At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Research Grants 35 show all


$1.7M
2012

$138.8K
2013

$12M
2014

$44.2M
2015

$967.5K
2016

Publications 1,847 show all

  • 143
    Thalidomide/analogs & derivatives
  • 59
    Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • 52
    Multiple Myeloma/drug therapy
  • 28
    Myelodysplastic Syndromes/drug therapy
  • 24
    Pancreatic Neoplasms/drug therapy
  • 21
    Antineoplastic Agents/therapeutic use
  • 20
    Antineoplastic Agents/pharmacology
  • 20
    Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • 18
    Leukemia, Myeloid, Acute/drug therapy
  • 17
    Psoriasis/drug therapy

Patents 5,985show all

  • 1,546
    A61K - Preparations for medical, dental, or toilet purposes
  • 781
    C07D - Heterocyclic compounds
  • 311
    C07C - Acyclic or carbocyclic compounds
  • 222
    C08G - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
  • 203
    C12N - Microorganisms or enzymes
  • 194
    Y02A - Technologies for adaptation to climate change
  • 161
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 153
    C07K - Peptides
  • 113
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 101
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations

Clinical Trials 1,642show all

570Phase 2394Phase 3240Phase 1163Phase 1/Phase 2135N/A45Other

SEC Filings show all


262
8-K

75
10-Q

24
10-K

Contact Information

Warren, NJ
United States